A healthcare reform bill with a government-run insurance option faced an uncertain future in the Senate on Tuesday, with many centrist Democrats uncommitted and Senator Joe Lieberman strongly opposed.
Senate Democratic leader Harry Reid said on Monday the Senate's sweeping healthcare reform bill would include a government-run insurance plan that lets states opt out of participation if they choose.
The U.S. healthcare system is just as wasteful as President Barack Obama says it is, and proposed reforms could be paid for by fixing some of the most obvious inefficiencies, preventing mistakes and fighting fraud, according to a Thomson Reuters report released on Monday.
Healthcare companies are reaping the benefits of a global swine flu pandemic, brightening what might otherwise have been a dismal third quarter and bringing new focus on the market for vaccines.
Health reform negotiations have moved behind closed doors in Congress, but chances are high that a bill will pass this year -- even if it doesn't do all that much to revamp the nation's swelling $2.5 trillion health care system.
House of Representatives Speaker Nancy Pelosi said on Tuesday new estimates showed a healthcare overhaul drafted by Democrats would reduce the U.S. budget deficit over 10 years and cost less than $900 billion.
Education provider Corinthian Colleges Inc said it agreed to acquire Heald Capital, the parent company of Heald Colleges, in a cash deal valued at about $395 million, including debt.
Boston Scientific Corp on Monday reported a quarterly net profit, compared with a year-ago loss, but cut its full-year earnings outlook, citing weakness in the market for implantable heart defibrillators.
Using arguments about the social benefits of healthcare reform may galvanize Democrats but they leave Republicans cold, U.S. researchers reported on Thursday.
Maine Senator Olympia Snowe became the most-watched lawmaker in the U.S. healthcare debate by following one of the oldest and most pragmatic of maxims -- that all politics is local.
Democrats opened difficult talks on healthcare reform in the U.S. Senate Wednesday, promising to bridge party divisions on a government-run insurance plan and paying for the overhaul.
Abbott Laboratories Inc said its third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc.
A key U.S. Senate committee endorsed a sweeping healthcare overhaul on Tuesday, gaining the support of an influential Republican and delivering President Barack Obama a victory on his top domestic priority.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and heart stents disappointed, sending its shares down 2.4 percent.
A key U.S. Senate committee endorsed a sweeping healthcare overhaul on Tuesday, gaining the support of an influential Republican and delivering President Barack Obama a victory on his top domestic priority.
Republican senator Olympia Snowe announced Tuesday that she will vote in favor of the Senate Finance Committee health care reform bill.
The Dow and S&P 500 fell on Tuesday after Johnson & Johnson reported disappointing third-quarter sales, while the Nasdaq edged up after Cisco Systems Inc announced a large acquisition.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and heart stents disappointed, sending its shares down 2.5 percent.
U.S. President Barack Obama's push for sweeping healthcare reform was poised to clear a key Senate hurdle on Tuesday, opening a new phase in the raging debate over his top domestic priority.
Stocks fell on Tuesday, threatening to break a six-day winning streak, as Johnson & Johnson's third-quarter sales figures disappointed investors.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and cardiac stents disappointed, sending its shares down more than 2 percent.
Johnson & Johnson posted weaker-than-expected quarterly revenue on Tuesday as sales of prescription drugs and cardiac stents disappointed, sending its shares down more than 2 percent.
